What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?

Advances in Therapy

Volumn 28, Issue 9, 2011, Pages 716-727

  De La Sierra, Alejandro ^a   Salazar, Jorge ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Global Epidemiology   (Spain)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Cardiovascular disease; Diabetes; Diabetic nephropathy; Direct renin inhibitors; Hypertension; Renin angiotensin system

Indexed keywords

ALISKIREN; AMLODIPINE; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LOSARTAN; NISOLDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN ANGIOTENSIN SYSTEM INHIBITOR; RENIN INHIBITOR; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY INJURY; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK MANAGEMENT; SIDE EFFECT;

AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES COMPLICATIONS; DIABETIC NEPHROPATHIES; FUMARATES; HUMANS; HYPERTENSION; RENIN;

EID: 82455199268     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0049-6     Document Type: Review

References (50)

1. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension. 2001;37: 1047-1052 (Pubitemid 32304002)
2. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52: 639-672
3. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens. 2005;23(suppl. 1): S9-S17
4. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fribrosis. Diabetes. 2008;57: 3297-3306
5. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348: 383-393 (Pubitemid 36159355)
6. Gæde P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358: 580-591 (Pubitemid 351214285)
7. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370: 829-840
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342;145-153 (Pubitemid 30051645)
9. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355: 253-259
10. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317: 713-720
11. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359: 1565-1576
12. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338: 645-652 (Pubitemid 28108434)
13. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21: 597-603 (Pubitemid 28172941)
14. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353: 611-616 (Pubitemid 29087980)
15. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker- based treatment regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24: 2091-2096 (Pubitemid 33716527)
16. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354: 1751-1756
17. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359: 995-1003 (Pubitemid 34286536)
18. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359: 1004-1010 (Pubitemid 34286537)
19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme therapy on diabetic nephropathy. N Engl J Med. 1993;329: 1456-1462 (Pubitemid 23335891)
20. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351: 28-31
21. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351: 1941-1951 (Pubitemid 39447135)
22. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364: 907-917
23. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Eng J Med. 2001;345: 870-878
24. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation. 2002;106: 672-678 (Pubitemid 34851925)
25. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med. 2001;345: 861-869
26. Lewis ED, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med. 2001;345: 851-860
27. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358: 1547-1559
28. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165: 1410-1419 (Pubitemid 40973424)
29. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362: 1575-1585
30. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366: 895-906 (Pubitemid 41265663)
31. Ostergren J, Poulter NR, Sever PS, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: Blood pressure-lowering limb: Effects in patients with type II diabetes. J Hypertens. 2008;26: 2103-2111
32. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359: 2417-2428
33. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375: 1173-1181
34. Weber MA, Bakris GL, Jamerson K, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010;56: 77-85
35. Krop M, Garrelds IM, de Bruin RJ, et al. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension. 2008;52: 1076-1083
36. Masson S, Solomon S, Angelici L, et al. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: Data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail. 2010;16: 964-970
37. Verma S, Gupta M, Holmes DT, et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J. 2011; Mar 17 [Epub ahead of print]
38. Hollenberg NK. Direct renin inhibition and the kidney. Nat Rev Nephrol. 2010;6: 49-55
39. Taylor AA, Anderson DR, Arora V, et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren in patients with diabetes: A pooled analysis of 10 randomized trials. Diabetes Care. 2007;30(suppl.): A129
40. Doulton TWR, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005;45: 880-886 (Pubitemid 40628932)
41. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148: 30-48 (Pubitemid 351688350)
42. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372: 547-553
43. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8: 190-198 (Pubitemid 351166266)
44. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet. 2007;370: 221-229 (Pubitemid 47069535)
45. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119: 530-537
46. Solomon SD, Shin SH, Shah H, et al. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarctions with systolic dysfunction. Eur Heart J. 2011;32: 1227-1234
47. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358: 2433-2446 (Pubitemid 351793017)
48. Persson F, Rossing P, Reinhardt H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care. 2009;32: 1873-1879
49. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care. 2010;33: 2304-2309
50. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplat. 2009;24: 1663-1669.